A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
Clinical trial NCT00851734 · COMPLETED
Trial details
- NCT number
- NCT00851734
- Sponsor
- Lux Biosciences, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-01
- Primary completion
- 2009-03-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.